Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TXG | CLUSTER | neutral | 3/10 | CEO Serge Saxonov and CFO Adam Taich sold a combined ~$2.25M in open-market sales on August 24, 2026, at ~$63/share. Thi | Aug 26, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider sales at Twist Bioscience, totaling ~$2.50M over a week, with the CEO, CFO, COO, and other senior e | Aug 26, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and President/COO Patrick Finn, sold a total of $8.48M in s | Aug 22, 2026 |
| ILMN | CLUSTER | bearish | 4/10 | Director Keith Meister sold ~$4.0M in shares on Aug 19, and SVP Jakob Wedel Christensen sold $198K on Aug 18, totaling $ | Aug 21, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three Twist Bioscience insiders — CEO Emily Leproust, President/COO Patrick Finn, and Director Katryn Blake — sold a com | Aug 21, 2026 |
| TXG | COURT-RULING | bearish | 7/10 | The Federal Circuit affirmed PTAB decisions invalidating all claims of three 10x Genomics patents (’981, ’197, ’013) as | Aug 20, 2026 |
| TXG | INST-CLUSTER | mixed | 5/10 | A mixed institutional cluster in TXG for 2026-Q2 shows 12 buyers adding $283.3M in new holdings, led by major quant and | Aug 19, 2026 |
| TXG | CLUSTER | neutral | 3/10 | Two 10x Genomics directors sold a combined $1.28M in open-market transactions over a 7-day window. Director Stuelpnagel | Aug 18, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina completed a $300M public offering of 4.950% notes due 2029. Net proceeds, together with cash on hand, will be u | Aug 17, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Multiple Twist Bioscience insiders, including CEO Emily Leproust, sold a combined $6.37M of stock over a 7-day window. T | Aug 15, 2026 |
| BEAM | INST-CLUSTER | bullish | 5/10 | Eight institutional investors accumulated $59.7M in BEAM during Q2 2026, led by Morgan Stanley doubling its stake to $67 | Aug 15, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Twist Bioscience CEO Emily Leproust sold $14.2M of stock via a derivative exercise-and-sell transaction, while two direc | Aug 14, 2026 |
| FATE | PRESS-RELEASE | bullish | 5/10 | Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for | Aug 14, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate o | Aug 13, 2026 |
| TWST | 144 | neutral | 2/10 | Director Katryn Blake filed a Form 144 to sell 2,240 shares of Twist Bioscience common stock, valued at approximately $2 | Aug 12, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Twist Bioscience CEO Emily Leproust sold $14.2M in stock on Aug 10, 2026, following the company's strong Q3 earnings bea | Aug 12, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina issued $300M of 4.950% notes due 2029 via an underwritten public offering. The net proceeds, together with cash | Aug 12, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider sales at Twist Bioscience totaling $4.39M occurred within 9 days of a strong Q3 2026 earnings beat | Aug 12, 2026 |
| BNGO | 8-K | mixed | 5/10 | Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31% co | Aug 10, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of five Twist Bioscience insiders, including the CEO, President/COO, and CAO, sold a total of $2.35M in stock | Aug 8, 2026 |
| ILMN | CLUSTER | bearish | 6/10 | Director Keith A. Meister sold a large block totaling ~$149M over two days, representing roughly 0.5% of ILMN's market c | Aug 7, 2026 |
| TWST | 144 | neutral | 3/10 | Director Robert Chess filed a Form 144 notice to sell 18,417 shares of Twist Bioscience common stock, valued at approxim | Aug 7, 2026 |
| ILMN | CLUSTER | bearish | 6/10 | Director Keith A. Meister sold a massive $150.4M worth of ILMN common stock over two days (Aug 4-5), plus an additional | Aug 7, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and coll | Aug 6, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Five Twist Bioscience insiders, including CEO Emily Leproust and President/COO Patrick Finn, sold a combined $884K in op | Aug 6, 2026 |
| FATE | CLUSTER | bearish | 5/10 | Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions | Aug 6, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| CRSP | PRESS-RELEASE | bullish | 6/10 | CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reache | Aug 3, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate | Aug 3, 2026 |